Improved GI tolerability with monthly ibandronate in women previously using weekly bisphosphonates

Neil Binkley, Mark G. Martens, Stuart L. Silverman, Richard J. Derman, Maria Greenwald, Joseph D. Kohles, Gloria A. Bachmann

Research output: Contribution to journalArticlepeer-review

14 Scopus citations

Abstract

OBJECTIVE: This subanalysis of CURRENT, an open-label, 6-month, multicenter study, assesses changes in gastrointestinal (GI) tolerability with once-monthly oral ibandronate in women who switched from once-weekly bisphosphonates and had reported GI symptoms with their previous weekly bisphosphonate regimen. METHODS: Postmenopausal women currently taking a weekly bisphosphonate switched to 150 mg monthly ibandronate. At the start of the treatment phase and after 6 months of therapy, all participants completed the Osteoporosis Patient Satisfaction Questionnaire (OPSAT-Q™), a validated instrument consisting of four domains: convenience, satisfaction, quality of life, and side effects. This subanalysis assessed GI tolerability in those women who reported GI symptoms at baseline in the side effects domain of OPSAT-Q™ and change in satisfaction in those who had reported stomach upset within 48 hours of taking their previous bisphosphonate at screening. RESULTS: Of women who reported GI symptoms at baseline, >60% reported an improvement in heartburn or acid reflux after switching to monthly ibandronate. Further, >70% reported improvements in stomach upset (excluding heartburn or acid reflux). Of those women who reported stomach upset within 48 hours of taking their previous weekly bisphosphonate at screening (n = 89), >80% reported improved overall satisfaction compared with baseline. Monthly ibandronate was generally well tolerated. CONCLUSION: A majority of women who experienced GI tolerability issues with weekly bisphosphonates reported improvements in GI symptoms after transitioning from a weekly bisphosphonate to monthly ibandronate for 6 months.

Original languageEnglish (US)
Pages (from-to)486-492
Number of pages7
JournalSouthern Medical Journal
Volume102
Issue number5
DOIs
StatePublished - May 2009

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Keywords

  • Bisphosphonates
  • Gastrointestinal intolerance
  • Ibandronate
  • Osteoporosis

Fingerprint

Dive into the research topics of 'Improved GI tolerability with monthly ibandronate in women previously using weekly bisphosphonates'. Together they form a unique fingerprint.

Cite this